In the setting of MPN, we recently demonstrated that an increased/decreased proportion of circulating platelet (CD61+CD62P+)-/megakaryocyte (CD61+CD62P-)-EVs is observed in patients with myelofibrosis (MF) and essential thrombocythemia (ET). Here, SELP is linked to myeloproliferative neoplasm.